Hypofractionated adjuvant whole breast radiotherapy: progress and prospects

Area of Science:

• Oncology
• Radiotherapy
• Breast Cancer Treatment

Background:

• Adjuvant radiotherapy is standard for early breast cancer.
• Hypofractionation involves larger radiation doses per fraction.
• Concerns exist regarding safety and efficacy of hypofractionated schedules.

Purpose of the Study:

• To evaluate the safety and efficacy of hypofractionated adjuvant radiotherapy schedules.
• To address concerns about heart tolerance and treatment duration.
• To inform the routine adoption of shorter radiotherapy schedules.

Main Methods:

• Analysis of published randomized trials involving over 7000 women.
• Comparison of hypofractionated schedules (15- or 16-fractions) with conventional fractionation.
• Assessment of outcomes including tumor control and late adverse effects.

Main Results:

• Hypofractionated schedules (2-3 Gy/fraction) are confirmed safe and effective with appropriate dose adjustments.
• Concerns regarding heart tolerance and follow-up duration are deemed unnecessary for 15- or 16-fraction schedules.
• Dose escalation in high-risk subgroups may increase late adverse effects more than tumor control, necessitating a dose-volume effect approach.

Conclusions:

• 15- or 16-fraction schedules of adjuvant radiotherapy are suitable for women with early breast cancer undergoing breast conservation surgery.
• Hypofractionation, including a 5-fraction regimen, shows promise and should be considered for routine adoption.
• Further research into dose-volume effects is crucial for optimizing hypofractionated radiotherapy in specific patient subgroups.